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Papillary Thyroid Carcinoma 
Intertwined with Hashimoto’s 
Thyroiditis: An Intriguing 
Correlation
Maria V. Deligiorgi and Dimitrios T. Trafalis
Abstract
Illustrating the ancient link connecting inflammation with cancer, the correla-
tion of papillary thyroid carcinoma (PTC) with Hashimoto’s thyroiditis (HT) has 
long been pursued as intersection of autoimmunity-induced chronic inflammation 
and tumor-induced immunity. The dramatic rise of the incidence of PTC οver the 
last decades—the main culprit for “thyroid cancer (TC) epidemic”—parallels the 
increasing incidence of HT, potentially reflecting a pathogenetic link that could 
be harnessed in diagnostics and therapeutics. Prompted by this perspective, in the 
present chapter, we dissect the hitherto elusive interrelationship of PTC with HT, 
focusing on four issues: firstly, an unresolved conundrum is whether PTC emerges 
due to or notwithstanding immune response or mirrors the “tumor defense-induced 
autoimmunity.” Secondly, the interrelationship of HT with PTC may be merely epi-
phenomenon of selection bias inherent in thyroidectomy series. Thirdly, the impact 
of HT on coexistent PTC is equivocal—host protective versus tumor protective. 
Fourthly, translating serum concentrations of thyroid autoantibodies and thyroid-
stimulating hormone (TSH) into predictive and prognostic PTC biomarkers 
dichotomizes, till now, the researchers. In the era of precision medicine, illuminat-
ing whether HT precipitates PTC or vice versa is awaited with anticipation in order 
to refine the preventive and therapeutic policy counteracting “TC epidemic.”
Keywords: papillary thyroid carcinoma, hashimoto’s thyroiditis,  
anti-thyroglobulin autoantibodies, anti-thyroperoxidase autoantibodies,  
thyroid-stimulating hormone
1. Introduction
Initially reported by Dailey et al. in 1955, the correlation of papillary thyroid 
carcinoma (PTC)—the most common thyroid cancer (TC) histotype—with 
Hashimoto’s thyroiditis (HT) [1] has long been pursued, rekindling the ancient 
link between inflammation and cancer [2]. Bearing in mind the rising incidence 
of PTC over the last decades [3], establishing causality between PTC and HT—
an issue highly contested—could lay the groundwork for a preventive policy. 
Moreover, harnessing the interrelationship of PTC with HT could refine thera-
peutics with respect to PTC. The present chapter dissects the correlation of PTC 
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with HT, delving into a strongly insinuated immunological link. A comprehensive 
review of current literature emphasizes on the bewildering clinical significance 
of the interrelationship of PTC with HT. The intriguing predictive and prognostic 
value of serum concentrations of thyroid autoantibodies and thyroid-stimulating 
hormone (TSH) in the context of PTC coexistent with HT paints a more nuanced 
and sophisticated picture.
2. Tailoring the treatment of PTC: where does coexistent HT stand?
Thyroid cancer (TC) is the most common endocrine malignancy [4], though 
comprising only 2.1% of global cancer burden [5]. It is estimated that 52,070 new 
TC cases will occur in 2019 in the United States, while 2170 patients will die of this 
cancer type [6]. Derived from follicular epithelial cells, PTC constitutes the most 
common TC subtype in iodine sufficient areas, accounting for 85% of differenti-
ated TC (DTC) [7] and 70–80% of TC [8]. In light of the interface between “TC 
epidemic” and “epidemic of diagnosis,” a true increase of the incidence of PTC due 
to environmental, hormonal, and lifestyle risk factors appears to be merged with 
overdiagnosis of subclinical disease owing to meticulous screening [3, 9–11].
The indolent nature of PTC imposes a paradigm shift from ameliorating 10-year 
survival rates exceeding 90% to eliminating the recurrence incidence that hovers 
at 15–30% [12]. Individualization of therapeutic approach is deemed to confront 
the emerging challenges [13]. Seminal studies [4, 14, 15] recently illuminated the 
“dark matter” of the previously unidentified driver genetic events in 96% of PTC 
[4], being translated into molecular-based risk-adapted therapeutic strategies [7]. 
Although surgery is the cornerstone of treatment of PTC, a tailored approach with 
respect to the extent of thyroidectomy and lymph node dissection, the radioiodine 
ablation, and the management of radioiodine-refractory recurrent/metastatic 
disease has been endorsed [7].
Provided that the clinical relevance of the increasingly reported interrelation-
ship of PTC with HT is clarified, the incorporation thereof in current PTC risk 
stratification systems may empower a personalized treatment. This perspective is 
anticipated to build on accomplishing a fine-tuned balance in terms of decision-
making concerning PTC, precluding both overestimating an innocent disease and 
ignoring a metastatic potential.
3. HT at a glance
HT, originally designated as “struma lymphomatosa” by Dr. Hakaru Hashimoto 
in 1912 [16], is the most common autoimmune thyroid disease and the most com-
mon cause of hypothyroidism in iodine sufficient areas, showing a worldwide 
annual incidence varying from 0.3 to 1.5 cases per 1000 individuals [17]. An 
insightful approach concerning the multifactorial etiology of HT has been proposed 
by Weetman et al.: aligned in a way reminiscent of the wholes of the Swiss cheese 
are genetic factors acting as susceptibility loci—major histocompatibility human 
leukocyte antigen (HLA) genes, immunoregulatory genes, thyroid specific genes-
environmental factors—excess iodine intake, viral infections, stress, endocrine 
disruptors—as well as non-modifiable intrinsic factors—female sex, parity, age. 
Traversed by a hypothetical arrow, this conceivable line translates in a catastrophic 
event [18].
The histopathologically confirmed HT is characterized by diffuse lymphocytic 
infiltrate, formation of lymphoid follicles with germinal centers within normal 
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thyroid tissue [19], and, potentially, atrophy of parenchymal tissue gradually 
replaced by fibrous tissue [20]. The identification of the autoantibodies hallmark 
of HT in 1936 [21] paved the way for Rose and Witebsky to designate HT as the 
archetype of autoimmune destructive disorders [22]. Whereas the pathogenesis 
of HT is unclear, crucial is considered the imbalance between T-helper (Th)2 
cells—Th CD (cluster of differentiation)4+ cells credited with stimulation of 
B cells, which in turn produce thyroid autoantibodies- and Th1 cells-cytotoxic 
Th CD4+ cells directly attacking the thyroid follicular cells. This concept has 
been refined by the imbalance between Th17 cells and Th cells producing mainly 
IL-17, involved also in carcinomas- and T regulatory (Treg) cells-Th CD4+ cells 
deemed to halt the immune response [23]. Especially, an increased TH17/Treg 
ratio ascribed to both enhancement of TH17 expression and decrease of Treg is 
involved in the pathogenesis of HT [24]. Incriminated for the depletion of thyro-
cytes in HT is principally the autocrine/paracrine Fas-/Fas ligand (FasL)-induced 
extrinsic apoptotic pathway [24, 25].
4.  Rationality in the investigation of the interrelationship of  
PTC with HT
Apart from the well-established connection of HT with thyroid lymphoma 
[26], which is beyond the scope of the present chapter, the association of TC with 
HT concerns almost exclusively the PTC [27], alluding to a discriminating, though 
unknown, pathogenetic link.
Since PTC is conceived as the main culprit for the explosive rise of TC incidence 
[3], the hypothesis that the increasing incidence of HT hastens the “TC epidemic” 
is appealing. Considering that the inflammation has been envisaged as the “seventh 
hallmark of cancer” [28], the autoimmunity-induced inflammatory milieu [29] 
merits further interrogation as the missing piece in the puzzle of the interrelation-
ship of PTC with HT.
An alternative explanation that cannot be ruled out is that third extraneous 
variables actually cause the coexistence of PTC with HT. Indeed, both PTC and 
HT are precipitated by an interplay among genetic factors and environmental 
influences most of which are shared by the two entities. Emphasis is placed on 
risk factors implicated in the pathogenesis of both PTC and HT, such as female 
predominance, excess iodine intake, and exposure to radiation [30–34], implying a 
spurious correlation.
Nonetheless, a common origin of PTC and HT from cancer stem cells expressing 
p63 proteins—homologs of p53 proteins postulated to regulate squamous stem cell 
commitment—has been suggested. In fact, the cancer stem cells constitute plu-
ripotent cells deemed to remain undifferentiated or undergo benign squamoid and 
glandural maturation or be differentiated to follicular epithelial cells, harboring the 
potential to elicit both PTC and HT [35, 36].
The interrelationship of PTC with HT spurs a realm of intense research, princi-
pally in four respects. Firstly, the pathogenetic link between HT and PTC remains 
elusive; however, accumulative evidence suggests that these two entities are immu-
nologically linked [29]. Secondly, some authors argue that this interrelationship is 
merely epiphenomenon of selection bias inherent in studies encompassing surgical 
series [37, 38]. Thirdly, equivocal—favorable versus unfavorable—is the impact 
of HT on the prognosis of concurrent PTC [39–48]. Finally, the translation of the 
serum concentrations of thyroid autoantibodies [49–56] and thyroid-stimulating 
hormone (TSH) [55, 57–63] into predictive and prognostic PTC biomarkers incites 
a perpetual conflict.
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5. Exploring the immunological link between PTC and HT
Compelling evidence insinuate that the PTC and the HT represent two extremes 
in the continuum of immune response. In cancer, dominant is an anti-inflammatory 
response dictated by cancer cells per se, counteracting the antitumor immune surveil-
lance. Quite the contrary, an overactivated inflammatory response owing to breakage 
of self-tolerance attacks host tissue cells, resulting in tissue damage in the context 
of autoimmune diseases. Despite the fundamental differences between the tumor 
microenvironment and the autoimmune milieu, certain parallel aspects of these 
two landscapes have been recognized [64]. For instance, the macrophages (M) and 
the neutrophils (N)—cells of myeloid origin—are encountered in both cancer and 
autoimmunity that act as well-coordinated partners to orchestrate the innate immune 
attack. Showing plasticity, these cells transition from proinflammatory M1/N1 polar-
ization, devoted to kill pathogens or cancer cells, to anti-inflammatory M2/N2 polar-
ization, dedicated to repair tissue damage and promote angiogenesis. A shift toward 
M2 macrophage polarization is a core component of tumor microenvironment, 
observed in autoimmune milieu as well, providing a hint to the interface thereof. 
Furthermore, supportive of the tumor-promoting M2 macrophage polarization is the 
local hypoxic milieu inherent in both autoimmune and cancerous diseases [64].
The elucidation of the continuum of immune response could provide insights into 
the pathogenetic background of the coexistence of PTC with HT. Given that the mac-
rophage phenotype M2 is considered tumor-promoting contrary to the antitumor 
effect of M1 phenotype, an appealing hypothesis connecting PTC with HT is derived 
from the intrathyroidal immune profiling of euthyroid HT conducted very recently 
by Imam et al. [65]. The immune infiltrate in euthyroid HT proved to contain low 
count of natural killer (NK) cells, facilitating the differentiation of the macrophage 
phenotype M0 to the M2 phenotype, which in concert with the observed low count of 
M1 macrophages may interpret the higher risk of PTC inherent in euthyroid HT [65].
Interestingly, overexpression of Toll-like receptors (TLR)—cell surface recep-
tors credited with recognition of pathogen-related molecules, crucial for activation 
of innate and adaptive immunity—is detected immunohistochemically in human 
thyrocytes surrounded by immune cells in all patients with HT. The high basal TLR3 
mRNA levels observed in PTC, reinforcing the shared immunological landscape, 
are consistent [66, 67].
Dissecting the interface of HT with PTC is expected to unveil novel targets for 
immunomodulation. For instance, triggering the innate immunity via the TLR5 
agonist flagellin, being already in clinical trials as inducer of NK activation [68], 
could be interrogated as a modality to reverse the M2 macrophage phenotype in 
PTC coexistent with HT.
In pursuit of the immunological link connecting PTC with HT, three hypotheses, 
rather interrelated, shape a conceptual framework outlined below.
5.1  Thyroid malignancy develops despite immune response in the  
 context of HT
Manifold mechanisms have been proposed to underlie the escape of PTC cells 
from immune response in the context of autoimmunity: (i) the ability of PTC 
cells to manipulate the expression of immune-regulatory cytokines, editing the 
immune response; (ii) the enhancement of Treg known to suppress the NK cell 
effector functions, mainly the cytotoxicity; and (iii) the promotion of expression 
of specific surface molecules facilitating tumor development and growth, such as 
the membrane-bound transforming growth factor b (TGFb), histocompatibility 
antigen, class 1, G (HLA-G), FasL, and B7 homolog 1(B7H1) [28].
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Moreover, the interrelationship of PTC with HT may empower the escape of cancer 
cells from immune surveillance, consolidating the dogma that “cancer is a wound that 
never heals since tumor cells hijack the wound healing machinery for their own gain” 
[69]. In fact, a recently discovered “unexpected player”, the T cell double negative (DN) 
CD4(−) CD8(−), expressed both in PTC and in thyroid autoimmunity, downregulates 
the proliferation of activated T effector cells and the cytokine production, fostering 
an immunosuppressive microenvironment [70]. Favoring immune tolerance, the 
FOXP3+ Treg cells—crucial players of thyroid autoimmunity [71]—are encountered 
also in PTC [70]. The dendritic cells (DCs), beyond governing the autoimmune milieu, 
are also expressed in PTC, being responsible for the expansion of FOXP3+ Treg cells, 
allowing the tumor immune evasion and, thus, enabling the PTC progression [72].
5.2 Thyroid malignancy develops owing to thyroid autoimmunity
The first detection of lymphocytes in neoplastic tissues by Virchow in 1863 
[73] paved the way for the endorsement of chronic inflammation as a precipitating 
factor for certain cancer types. In that respect, thyroid gland could be conceived as 
an intersection of HT-induced chronic inflammation and cancer; however, a causal 
relationship is yet to be defined. In light of the cancer-related inflammation (CRI), 
the concurrence of PTC with HT might reflect either the malignant transforma-
tion ascribed to an autoimmunity-induced chronic inflammatory milieu (extrinsic 
pathway) or the inflammatory response to tumor (intrinsic pathway) [74].
The perpetually overactive immune response in the context of HT initiates an 
inflammatory vicious cycle with the potential to gear the journey of normal cells 
toward malignancy, rendering the interrelationship of PTC with HT the epitome of 
the extrinsic pathway of CRI [74].
Central in the extrinsic pathway is the “smoldering inflammation,” an ungoverned 
inflammatory milieu orchestrated by immune/inflammatory cells, involving macro-
phages, immature DCs, and mast cells, expressing a myriad of cytokines, chemokines, 
and growth factors, such as interleukin (IL)-1b, tumor necrosis factor a (TNFa), IL-6, 
(C-C motif) ligand 2 (CCL2)/monocyte chemoattractant protein 1 (MCP-1), CXC 
chemokine ligand (CXCL8)/IL-8, vascular endothelial growth factor (VEGF), as 
well as reactive oxygen species (ROS) and reactive nitrogen species (RNS), spurring 
tissue damage, neo-angiogenesis, and tissue remodeling [75, 76]. Implicated in this 
milieu is the hypoxic microenvironment, inherent in both PTC and HT, favoring the 
progression of tumor, reinforcing, among others, the neo-angiogenesis and the shift 
of metabolism toward anaerobic glycolysis [64].
Overexpression of cyclooxygenase-2 (COX-2)—an enzyme involved in initiation [77] 
and progression of thyroid tumors [78]—and inducible nitric oxide synthases (iNOS), 
key elements of CRI, has been observed in epithelial cells of lymphocytic thyroiditis, 
follicular adenoma, and PTC contrary to the absence or the limited expression thereof in 
normal thyroid epithelium, potentially linking carcinogenesis to autoimmunity [79].
Intertwined with the extrinsic pathway is the intrinsic pathway: genetic altera-
tions caused by DNA damage induced by the “smoldering inflammation” [80] 
trigger a proinflammatory transcriptional program [74]. For instance, the oncogene 
RAS is involved in the induction of chemokine CXCL8 [75], an inflammatory 
mediator of both cancer [75] and autoimmunity [64]. Moreover, phosphatase and 
tensin homolog (PTEN) mutation, a key element of the oncogenic phosphoinositide 
3-kinase (PI3K)/protein kinase B (AKT) pathway, leads to upregulation of hypoxia-
inducible factor-1 (HIF1), which, in turn, upregulates the CXC chemokine receptor 
4 (CXCR4) [75], well-recognized player of autoimmunity [81]. Accordingly, the 
observed activation of the PI3K/AKT pathway in HT, PTC, and HT coexistent with 
PTC contrary to the absence of activation thereof in normal follicles is rational [82].
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Illustrating the common molecular background shared by PTC and HT, the 
rearranged during transfection (RET)/PTC rearrangements—landmarks of PTC—
are detected in 95% of HT [83]. Moreover, the RET/PTC1 rearrangement has been 
detected more frequently in PTC coexistent with autoimmunity than PTC alone 
(31% versus 13%, respectively) [84]. The inflammatory milieu fosters the genesis of 
RET/PTC rearrangements either via secreting ROS and RNS [85]—the main culprit 
for mutagenic-mediated DNA damage [2]—or sustaining the survival of thyroid 
cells that harbor RET/PTC rearrangements.
The oncogenic RET/PTC-RAS-BRAF-mitogen-activated protein kinase (MAPK) 
cascade [74] may connect the oxyphil cell metaplasia of HT with PTC, considering 
the enhancement of the expression of RET, nuclear RAS, and extracellular signal-
regulated kinases (ERKs)—core components of MAPK cascade—not only in PTC 
but also in oxyphil cells in the context of HT [86].
Further, experimental data unravel that the RET/PTC1 exogenously expressed on 
normal human thyroid cells induces an inflammatory milieu involving crucial chemo-
kines and their receptors, promoting functions vital for tumor progression, such as pro-
liferation and survival of cancer cells [e.g., CXCR4/CXCL1] as well as neo-angiogenesis 
(e.g., CXL1, 2, 3, 5, 6, and 8) [87].
Additionally, a constellation of RET/PTC1-induced molecules fosters the gen-
esis and evolution of cancer, including (i) matrix metalloproteinases (MMPs) and 
dipeptidyl peptidase IV (DPP IV), molecules crucial for tissue remodeling, tumor 
invasiveness, and neo-angiogenesis [87]; (ii) urokinase-type plasminogen activa-
tor (UPA) and urokinase-type plasminogen activator receptor (UPAR), involved in 
cancer progression and metastasis [87]; (iii) l-selectin [87], an adhesion molecule 
facilitating metastasis [88]; and (iv) osteopontin (OPN) and CD44, implicated in 
proliferation and invasion of transformed PCCl 3 cells, rat thyroid follicular cells [89].
An intriguing RET/PTC3-induced mechanism pivotal for tumor progression is 
the recruitment of CD11b+Gr1+ myeloid-derived suppressor cells, providing cancer 
cells with the advantage of evading immune surveillance [90, 91].
However, skepticism raise the technical limitations of the applied PCR tech-
niques and the lack of reproducibility of the results of studies detecting the RET/
PTC rearrangements in HT [92]. Furthermore, the equivocal nature of RET/PTC-
induced transcriptional program—tumor-promoting versus antitumor—should be 
considered [87].
5.3 The immune attack against PTC triggers thyroid autoimmunity
The association of PTC with HT seems more intricate than initially conceived 
in view of a seminal cyclic model governed by the overactive immune response, 
acting as a driving force for carcinogenesis, while being also a marker of tumor 
immunity [93]. An assumption that merits further exploration is whether the cross 
reaction of antitumor immunity with normal thyrocytes may precipitate HT in 
PTC patients genetically predisposed to thyroid autoimmunity, consolidating the 
hypothesis of “tumor defense-induced autoimmunity” [29]. With the advent of the 
era of cancer immunotherapy, new light on the coexistence of HT with PTC is shed 
by the increasingly reported development of HT as an adverse event of the mono-
clonal antibodies blocking programmed cell death (PD) protein 1 (PD-1) and PD 
ligand 1 (PD-L1). This revolutionary anticancer treatment unleashes the antitumor 
immunity at the expense of abrogating the self-tolerance, exemplifying the “tumor 
defense-induced” immunity [94]. For instance, a loss of circulatory PD1+ CD4+ and 
CD8+ T cells, an increase in peripheral CD56+CD16+ NK cells and an increase in 
activated monocytes have been implicated in pembrolizumab (anti-PD1 monoclo-
nal antibody)-induced thyroiditis [94].
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6. Does the coexistence of HT with PTC really exist?
An issue of major concern is whether the coexistence of PTC with HT is real or a 
myth nurtured by methodological pitfalls implicit in studies addressing this issue.
The great variety of the incidence of the coexistence of PTC with HT ranging 
from 0.5 to 38% [95] or, alternatively, from 5 to 85% is noticeable [96]. The results 
of the meta-analyses addressing the coexistence of PTC with HT are highly diver-
gent [40, 48, 96, 97], as depicted in Table 1. The broad array of the mean rate of 
PTC among patients with HT extending from 1.1 to 40.1% blurs the landscape  
[97]. Nevertheless, according to a systematic review, the correlation of PTC with 
HT is statistically significant with a relative risk (RR) of HT among PTC equal to 
2.36 and a RR of PTC among HT equal to 1.40 [98].
In an attempt to annotate the diverse epidemiological profile of the coexistence 
of PTC with HT, attention should be paid to the discrepancy among pertinent 
studies concerning the design, the enrolled populations, and the histopathologic 
definitions of HT [99]. Moreover, certain caveats hamper hitherto the interpreta-
tion of the lymphocytic infiltration and the positivity of thyroid autoantibodies. 
Firstly, thyroid lymphocytic infiltration confirmed on histology has been signifi-
cantly associated with PTC even in the absence of thyroid autoantibodies [100]. 
Secondly, the pattern of Tg recognition by anti-thyroglobulin autoantibodies 
(TgAbs) differs between autoimmune and non-autoimmune thyroid disorders, 
being more restricted in autoimmune disorders as compared with nodular goiter 
and PTC harboring no thyroid lymphocytic infiltration [101]. However, in PTC 
correlated with histopathologically confirmed HT, the pattern of Tg recognition 
does not differ from that observed in HT [101]. Thirdly, it should be mentioned that 
the thyroid autoantibodies may be detected in healthy individuals [102]. Finally, the 
discordance among available TgAbs assays should be considered [103].
Another hurdle in evaluating the coexistence of PTC with HT is the selection 
bias inherent in data derived from surgical specimens wherein the prevalence of 
PTC is a priori higher than that in fine needle aspiration biopsy (FNAB) studies. 
Reference Results
Moon et al. [48] PTC coexistent with HT is negatively associated with ETE (OR: 0.74, 95% CI, 0.68–0.81), 
LNM (OR: 0.82, 95% CI, 0.72–0.94), distant metastasis (OR: 0.49, 95% CI, 0.32–0.76), and 
recurrence (RR: 0.50, 95% CI, 0.41–0.61)
Lee et al. [96] Frequency of HT in PTC: ≈23%
2.8 times higher occurrence rate of HT in PTC than in benign thyroid diseases (p < 0.001)
2.4 times higher incidence of HT in PTC than in other TC (p < 0.001)
Significant association of PTC concurrent with HT with female sex (OR: 2.7; p < 0.001), 
multifocality (OR: 1.5, p = 0.010), absence of ETE (OR: 1.3, p = 0.002) and LNM (OR: 1.3, 
p = 0.041), long recurrence-free survival (HR: 0.6, p = 0.001)
Lai et al. [97] Range of mean rate of PTC among patients with HT: 1.12–40.11%
Overall pooled OR of PTC risk for HT (HT versus non-HT): 2.12 (95% CI, 1.78–2.52)
Singh et al. [40] 2.77 times elevated rate of PTC in patients with HT compared with control population (OR: 
2.77, 95% CI, 1.24–6.21)
1.89 times higher rate of HT in patients with PTC compared with other TC types (OR: 1.89, 95% 
CI, 1.02–3.50)
Increased PTC-free survival in patients with coexistent HT (r: 0.08, 95% CI, 0.05–0.12)
Increased overall survival in PTC patients with coexistent HT (r: 0.11; 95% CI, 0.07–0.14)
Abbreviations: CI, confidence interval; ETE, extrathyroidal extension; HR, hazard ratio; HT, Hashimoto’s thyroiditis, 
LNM, lymph node metastasis; OR, odds ratio; PTC, papillary thyroid carcinoma, RR, risk ratio; TC, thyroid cancer.
Table 1. 
Meta-analyses addressing the correlation of PTC with HT.
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Jankovic et al. showed that the average prevalence rate of PTC in HT patients 
differed significantly between FNAB and thyroidectomy studies: 1.20 and 27.56%, 
respectively. Likewise, the relative risk of PTC in HT patients extended from 0.39 
to 1.00 in the FNAB studies, significantly lower than that observed in the thy-
roidectomy studies (1.15–4.16) [37]. In that respect, Castagna et al. demonstrated 
absence of association of nodular HT with TC based on cytology. The same authors 
observed a significantly higher prevalence of DTC in nodular HT compared to 
nodular Graves’ disease, nodular goiter with either negative or positive thyroid 
autoantibodies, according to surgical series. This result raised the possibility of 
selection bias ascribed to the fact that 60.7% of patients with nodular HT under-
went surgery due to cytological data suspicious of thyroid malignancy [38]. The 
FNAB data from 10,508 patients revealing no statistically significant relationship 
between PTC and HT are consistent [104].
Nevertheless, the fear of the selection bias was abolished by the recent demon-
stration of a significant association of PTC with HT based on either pathological 
examination of surgical specimens or FNAB studies [60].
7. Effect of HT on coexistent PTC: host protective or tumor protective?
Irrespectively of whether HT is etiologically linked to PTC or merely judged 
“guilty by association,” the importance of this coexistence lies on its clinical 
significance. Since a complex immune network has been considered a core compo-
nent of PTC microenvironment, it is rational to assume that HT—the epitome of 
aberrant immune reaction—influences the progression of coexistent PTC [105]. 
In that respect, the positive association of a favorable outcome of coexistent PTC 
with HT, tumor-associated macrophage infiltration, and CD8+ lymphocytes 
highlights the antitumor potential of the immunological landscape intrinsic in HT 
[106]. The recently reported negative correlation of RORγt—a nuclear transcrip-
tion protein of Th17—with lymph node metastases in PTC concurrent with HT is 
consistent. In fact, RORγt is positively associated with the upregulation of caveolin 
1, a tumor suppressor gene [107]. Another plausible mechanism underlying the 
host-protective effect of HT coexistent with PTC could be the lower frequency 
of BRAF V600E mutation—a genetic alteration associated with aggressive PTC 
phenotype—in PTC concurrent with HT compared with PTC alone [41, 42].
A rich repertoire of features indicative of auspicious PTC prognosis are signifi-
cantly associated with coexistent HT, including increased relapse-free and overall 
survival [39], increased survival rate [96, 108], decreased risk of recurrence [108], 
lower rate [108] or absence of extrathyroidal extension [96], and lower rate [41] or 
absence of lymph node metastases [96], observed in PTC coexistent with HT com-
pared with PTC alone. The results of a recent meta-analysis including 71 published 
studies with 44,034 participants revealing that PTC coexistent with HT significantly 
correlated with reduced incidence of extrathyroidal extension, lymph node, and 
distant metastasis and increased recurrence-free survival duration compared with 
PTC alone are seminal [47]. Noticeably, the coexistence of HT with PTC has been 
proven an independent indicator of favorable prognosis of PTC [105], irrespectively 
of the extent of lymph node dissection [46], though inconsistently [108]. On the 
other hand, the reported absence of host-protective effect of HT on coexistent PTC 
[42–45] hampers the endorsement of HT as a prognostic PTC biomarker.
In fact, the inflammatory cell infiltration of tumor microenvironment plays an 
equivocal role, tumor-promoting versus antitumor, posing a “Dr. Jekyll or Mr. Hyde” 
enigma [109]. Challenging is the illumination of the precise factors that define the 
fate of cancer cells in the context of the interface of PTC with HT.
9Papillary Thyroid Carcinoma Intertwined with Hashimoto’s Thyroiditis: An Intriguing…
DOI: http://dx.doi.org/10.5772/intechopen.85128
8.  Thyroid autoantibodies in the context of HT coexistent with PTC: 
predictive and/or prognostic PTC biomarkers or not?
Whether HT constitutes the driving force for PTC or vice versa remains elusive; 
nevertheless, the thyroid autoantibodies, the landmark of HT, and especially the 
anti-thyroperoxidase autoantibodies (TPOAbs)—a more sensitive marker of HT 
than the TgAbs—merit interrogation as potential hallmarks of the interrelationship 
of PTC with HT.
A great body of evidence sustains that the positivity of thyroid autoantibodies 
translates into predictive and prognostic knowledge. In particular, the positivity 
of TPOAbs [49, 52, 53], TgAbs [51, 53, 110], as well as TPOAbs coexistent with 
TgAbs [52], has been shown to harbor a predictive value. Moreover, the positivity 
of TPOAbs [52, 57] and TgAbs [50–53, 110] has been designated as an independent 
predictive factor for thyroid malignancy in nodular goiter. Interestingly, the coexis-
tence of TgAbs and TPOAbs is associated with a PTC risk greater than that con-
nected with isolated positivity of either TgAbs or TPOAbs [52]. A host-protective 
role of TPOAbs in the context of coexistent PTC has been demonstrated [27, 54, 55], 
rationalized by the speculation that the TPOAbs exert a cytotoxic effect [110].
However, skepticism imposes a multivariate analysis failing to consolidate the 
host-protective effect of thyroid autoantibodies in the case of coexistent PTC [55]. 
Importantly, awareness raises the correlation of the positivity of thyroid autoanti-
bodies with features indicative of ominous PTC prognosis, such as advanced disease 
stage [52]. As a potential link between positive thyroid autoantibodies and aggres-
sive phenotype of PTC could be suggested the excess iodine intake that unmasks a 
cryptic epitope on Tg, triggering the development of TgAbs [33, 34], while exerting 
stimulative effect on the genesis of BRAF V600E mutation as well [111]. However, 
this hypothesis is debunked by the observation that the BRAF V600E mutation in 
DTC is inversely correlated with coexistent HT [42]. In the light of the foregoing, 
the designation of thyroid autoantibodies as predictive and/or prognostic biomark-
ers of PTC is not yet feasible.
9.  Elevated TSH levels in HT coexistent with PTC: the mediator of the 
effect of HT on PTC?
Considering that TSH constitutes a growth factor for thyrocytes [58], rational 
is the designation of increased, even within the normal range, serum TSH levels, 
in the case of PTC concurrent with HT, as a predictor of PTC risk [49, 52, 58] and a 
harbinger of aggressive tumor behavior [55, 59].
A strong argument in favor of the role of TSH in thyroid tumorigenesis is 
the detection of activating mutations of TSH receptors (TSH-R) in DTC [112]. 
Moreover, the cross-talk between the TSH-R/protein kinase A (PKA) signaling 
transduction and the well-recognized oncogenic pathways involving Wingless/int-1 
(Wnt), PI3K, and MAPK has been implicated in initiation and progression of TC 
[113]. However, many arguments against the pathogenetic role of TSH in TC have 
been raised [114–117].
Nevertheless, the demonstration of HT as a risk factor for PTC in univariate 
analysis while being a host-protective factor in multivariate analysis after control-
ling TSH levels should be mentioned [61]. Similarly, multivariate analysis showed 
that increased TSH levels were an independent risk factor of malignancy in most 
FNAB studies, albeit not consistently related to HT [60]. Consequently, the subclini-
cal or overt hypothyroidism due to autoimmune destruction of thyroid—and not HT 
per se—could be the real culprit for the increased PTC risk in the context of HT.
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Experimental data derived from mouse models suggest the TSH-induced signal-
ing mediated via cyclic adenosine monophosphate (cAMP) as a prerequisite for the 
BRAF V600E-stimulated PTC genesis, providing a plausible explanation for the 
implication of elevated TSH levels in PTC [62]. Furthermore, a protein kinase C 
(PKC)-mediated pathway has been demonstrated in vitro to transduce the TSH-
induced signaling, dictating the invasiveness and the growth of human follicular TC 
cell lines [118].
However, the reported association of subclinical hypothyroidism with a less 
aggressive PTC phenotype compared with euthyroidism cannot be ignored [119]. 
Consistent is the higher risk of DTC enclosed in HT requiring low levothyroxine 
(LT4) replacement doses as compared with HT-induced hypothyroidism requiring 
higher LT4 replacement doses [27]. A hypothesis mandating further exploration 
is that the toxic effect of TSH mediated by H2O2—an element essential for thyroid 
hormone synthesis being simultaneously a mitogenic and mutagenic factor—
concerns the residual functioning thyroid tissue, while sparing the completely 
destructed thyroid [27].
Intriguingly, according to the European Prospective Investigation into Cancer 
and Nutrition (EPIC) cohort, low TSH levels may induce DTC [63], likely form-
ing a less differentiated epithelium susceptible to malignant transformation [27]. 
Interestingly, two genetic variants predisposing to PTC located on 9q22.23 and 
14q13.3 have been also associated with low TSH levels [120]. Consequently, the 
perplexing role of TSH in PTC fuels a contention regarding the endorsement of 
TSH levels as predictive and/or prognostic biomarker of PTC.
10. Conclusions
Despite the major strides toward the elucidation of the correlation of PTC with 
HT, integrating coexistent HT per se, as well as thyroid autoantibodies and TSH 
levels into PTC risk stratification systems, awaits further consolidation. Translating 
the coexistence of PTC with HT into the therapeutic approach of PTC is currently 
uncertain. A burning question is whether the broad clinical spectrum of HT, mir-
roring the wide array of HT histopathology, defines the trajectory of the coexistence 
of PTC with HT. The designation of HT as a premalignant lesion or PTC as a pre-
cipitating factor for HT is thwarted by the blurred, till now, pathogenetic landscape. 
Illuminating the temporal precedence, a parameter sine qua non for the embrace-
ment of a causal relationship between PTC and TC, is daunting. Nevertheless, har-
nessing the immunological link between PTC and HT should guide future efforts in 
clinical research, aiming to widen the horizons of immunotherapy.
In the interim, active surveillance of HT cannot be undermined, since it yields a 
tangible perspective of a prompt therapeutic intervention in the case of coexistent PTC.
Nonetheless, striking is, to date, the dearth of solid evidence to guide clini-
cal decision-making on surveillance of HT based on the presumptive correlation 
thereof with PTC; in fact, a patient-oriented standard of care of HT should be 
applauded. Although thyroid ultrasonography (US) is not required for diagnosing 
and monitoring the majority of HT, an individualized approach should be endorsed 
in clinical settings. Bearing in mind the negativity of TPOAbs and/or TgAbs in 10% 
of HT patients [121] and approximately 20% of patients with subclinical hypothy-
roidism [122], identifying a hypoechoic or an inhomogeneous US thyroid pattern 
will provide invaluable information as regards the diagnosis of HT. Even though 
a thyroid/neck US is not routinely recommended unless a palpable thyroid lesion 
is detected [7], averting underdiagnosis of a PTC smaller than 1 centimeter (cm) 
in greatest dimension—the so-called papillary thyroid microcarcinoma—raises 
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awareness. In that respect, US could unravel a nodular variant of HT that merits 
further evaluation. The management of nodules in the context of HT is governed by 
the rules applied for any thyroid nodule irrespectively of HT, based on US-guided 
stratification of risk of malignancy [7]. FNAB is indicated in (i) nodules equal to 
or larger than 1 cm in greatest dimension presenting sonographic features of high 
or intermediate suspicion for PTC, (ii) nodules equal to or greater than 1.5 cm in 
greatest dimension presenting sonographic features of low suspicion for PTC, and 
(iii) nodules equal to or greater than 2 cm in greatest dimension presenting features 
of very low suspicion for PTC. Lower size cutoffs are embraced in the presence of 
clinical risk factors for PTC [7]. Pending the illumination of the clinical significance 
of the correlation of PTC with HT, clinicians should rely on their discretion and 
judgment, implementing the principle “primum non nocere.”
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CXCL CXC chemokine ligand
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HLA human leukocyte antigen
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IL interleukin
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MAPK mitogen-activated protein kinase
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